secwatch.observer — SEC 8-K summary
======================================

Issuer:     Translational Development Acquisition Corp. (TDAC)
CIK:        0001926599
Form:       8-K
Filed at:   2024-12-27T23:59:59+00:00
Accession:  0001104659-24-132134
Event type: other
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 3.02, 5.02, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SPAC Translational Development closes $172.5M IPO with full over-allotment
--------------------------------------------------------------------------

- IPO of 17.25M units at $10/unit raised $172.5M gross; units list on Nasdaq under TDACU.
- Simultaneous private placement of 7.075M warrants at $1.00/warrant raised $7.075M from sponsor and underwriter.
- Net proceeds of $174.225M placed in trust account; company has 18 months to complete a business combination.
- Michael B. Hoffman named CEO/Chairman; Avanindra C. Das CFO; Board includes Reddy, Keith, Kestenbaum, Jarratt.
- Directors appointed to audit, compensation, and nominating committees; indemnity agreements executed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1926599/000110465924132134/0001104659-24-132134-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1926599/000110465924132134/tm2422367d22_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-132134

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer